Blackstone bags Clarus, staking out a growing PhIII niche for itself in a rapidly changing biopharma industry
Blackstone likes life sciences. And now it’s diving in deep.
The private equity giant has completed a deal to buy Clarus, a busy life sciences investor with an extensive history of gambling on late-stage drug development.
With $2.6 billion under management, Clarus is a peanut on Blackstone’s $440 billion plate. But with $19 billion in healthcare deals completed and a vast portfolio of biotech facility space on its books, Blackstone has the resources to go much bigger in a field that has been exploding with new activity over the last few years.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.